Boston Scientific will eliminate jobs after discontinuing global sales of its Acurate aortic valve replacement systems that ...

The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement ...

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves ...

Boston Scientific leads in MedSurg and Cardiovascular with strong Q1 growth, solid margins, and smart acquisitions. Find out ...

Boston Scientific (NYSE:BSX) shares fell 4% after the company announced it will discontinue global sales of its ACURATE neo2 ...

Boston Scientific has pulled global sales of, and is no longer seeking FDA approval for, its Acurate neo2 and Acurate Prime aortic valve systems. In a May 28 Securities and Exchange Commission filing, ...

Camille Chang Gilmore, Boston Scientific’s global chief DEI officer announced she is leaving the company after two decades of ...

Boston Scientific ends global sales of ACURATE valves and halts FDA pursuit, citing rising regulatory burdens; expects to ...

Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

Boston Scientific Corp. closed 0.93% short of its 52-week high of $107.17, which the company achieved on February 5th.